Keywords: Alzheimer's Disease, Quantitative Imaging
Motivation: Existing glymphatic biomarkers like ALPS are limited by ROI constraints and variability, requiring a more reliable, non-invasive tool for early diagnosis.
Goal(s): This study aims to establish a more comprehensive biomarker for staging cognitive impairment by developing an automated, multi-ROI spectrum of ALPS (sALPS) analysis that mitigates observer bias and increases diagnostic sensitivity.
Approach: We analyzed sALPS mean and variance from diffusion MRI data in a large cohort, correlating these metrics with plasma biomarkers and applying machine learning for classification.
Results: Our sALPS indices demonstrated significant differentiation between cognitive stages, correlating strongly with plasma biomarkers and effectively classifying SCD and AD groups.
Impact: This study provides a novel, automated sALPS biomarker that enhances early detection of glymphatic dysfunction, potentially improving diagnostic precision and staging of cognitive impairment through its application in machine learning models for robust classification across cognitive stages.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords